Management of Heavy Menstrual Bleeding with Hemoglobin 7.2 g/dL
This patient requires immediate multidisciplinary intervention with supportive care (blood transfusion and/or IV iron), acute bleeding control with high-dose hormonal therapy or tranexamic acid, and iron supplementation—whether or not she receives transfusion—followed by definitive long-term menstrual management. 1, 2
Immediate Assessment and Stabilization
Check hemodynamic status immediately: Measure orthostatic blood pressure and pulse to assess volume depletion 3. With hemoglobin at 7.2 g/dL, this patient has severe anemia requiring urgent intervention.
Supportive care options include:
- Blood transfusion if hemodynamically unstable, actively bleeding heavily, or symptomatic (fatigue, dyspnea, tachycardia) 1
- IV iron infusion (iron dextran, ferric carboxymaltose, or iron sucrose) as an alternative or adjunct, particularly if transfusion is declined or bleeding is controlled 1, 4
- Recent evidence shows hemoglobin recovery occurs substantially even without transfusion when bleeding is controlled, though transfusion may be necessary in selected cases 5
The critical point: Iron supplementation is mandatory regardless of whether transfusion is given, as iron stores (ferritin) recover much more slowly than hemoglobin 2, 5.
Acute Bleeding Control
First-line medical management includes:
Tranexamic acid (antifibrinolytic):
- Oral: 1300 mg three times daily during bleeding
- IV: 10 mg/kg every 8 hours if unable to take oral
- Can be used immediately and is highly effective for acute control 1, 2, 3
High-dose hormonal therapy (if not contraindicated):
- Combined hormonal contraceptives: 1 pill every 8 hours until bleeding stops (typically 24-48 hours), then taper
- OR high-dose progestins: norethindrone 5-10 mg three times daily 3, 6
If medical management fails or bleeding is life-threatening:
- Intrauterine Foley catheter balloon tamponade for severe hemorrhage 1, 7
- Dilation and curettage with immediate LNG-IUS placement 7
- Endometrial ablation in select cases 7
Bridging Phase (Often Overlooked)
After acute bleeding stops, a bridging phase is critical to prevent recurrence while anemia improves 6. This vulnerable period requires:
- Continuous progestin therapy (norethindrone 5 mg daily) OR
- Continuous combined hormonal contraceptives (skip placebo pills) OR
- Depot medroxyprogesterone acetate injection for reliable amenorrhea 6
- Continue tranexamic acid during any breakthrough bleeding 6
This phase typically lasts 2-3 months until hemoglobin normalizes and definitive therapy can be safely implemented 6.
Iron Repletion (Mandatory)
Iron supplementation is required whether or not anemia is present 2:
Oral iron:
- Ferrous sulfate 325 mg (65 mg elemental iron) every other day on empty stomach (better absorbed and tolerated than daily dosing) 4
- Continue until ferritin >30 ng/mL, not just until hemoglobin normalizes 4
IV iron preferred if:
- Oral iron not tolerated or ineffective after 4-6 weeks
- Ongoing heavy bleeding despite treatment
- Need for rapid repletion 4, 8
- Single-dose IV iron formulations improve adherence and quality of life 8
Critical caveat: Ferritin recovery lags significantly behind hemoglobin improvement—patients may have normal hemoglobin but remain iron deficient for months 5. Check ferritin at follow-up, not just hemoglobin.
Long-Term Maintenance
Levonorgestrel-releasing IUD (LNG-IUS) is the most effective long-term option:
- Reduces menstrual blood loss by 71-95% at 6 months 9, 7
- Increases hemoglobin significantly (mean increase ~37 g/L) 7
- Dramatically improves quality of life 7
- Should be placed after bleeding is controlled and hemoglobin improves, not during acute bleeding 6
Alternative long-term options:
- Combined hormonal contraceptives (continuous or cyclic)
- Depot medroxyprogesterone acetate injections
- Oral progestins (norethindrone)
- Tranexamic acid during menses only 9
Evaluation for Underlying Bleeding Disorder
Screen for bleeding disorders in all adolescents and women with heavy menstrual bleeding requiring this level of intervention 3:
- Complete blood count with platelet count
- PT/aPTT
- Von Willebrand factor antigen and activity
- Factor VIII level
- Consider platelet function testing if above normal 3
Coordinate with hematology if bleeding disorder suspected or confirmed 1.
Follow-Up Strategy
Reassess at 4-6 weeks:
- Hemoglobin and ferritin levels (not just hemoglobin)
- Menstrual bleeding pattern (use PBAC score if available)
- Medication adherence and side effects
- Transition from bridging to definitive therapy if stable 6
Continue monitoring every 3 months until:
Common Pitfalls to Avoid
- Don't stop at hemoglobin normalization—iron stores must be repleted or anemia will recur 2, 5
- Don't place LNG-IUS during active heavy bleeding—control bleeding first, then place during bridging phase 6
- Don't forget the bridging phase—jumping directly from acute control to long-term maintenance risks recurrent bleeding 6
- Don't assume all hormonal therapy is contraindicated—even in patients with prior thrombosis, progestin-only options and local therapy (LNG-IUS) are generally safe 1
- Don't use oral iron daily—alternate-day dosing improves absorption and tolerability 4